1. Home
  2. BLND vs VNDA Comparison

BLND vs VNDA Comparison

Compare BLND & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blend Labs Inc.

BLND

Blend Labs Inc.

HOLD

Current Price

$1.70

Market Cap

418.2M

Sector

Technology

ML Signal

HOLD

Logo Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

HOLD

Current Price

$7.07

Market Cap

474.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLND
VNDA
Founded
2012
2002
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
418.2M
474.0M
IPO Year
2021
2005

Fundamental Metrics

Financial Performance
Metric
BLND
VNDA
Price
$1.70
$7.07
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$4.13
$14.90
AVG Volume (30 Days)
3.8M
3.8M
Earning Date
03-10-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
58.33
N/A
EPS
N/A
N/A
Revenue
$123,585,000.00
$216,105,000.00
Revenue This Year
$16.90
$21.35
Revenue Next Year
$15.83
$37.40
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.72
52 Week Low
$1.44
$3.81
52 Week High
$4.49
$9.91

Technical Indicators

Market Signals
Indicator
BLND
VNDA
Relative Strength Index (RSI) 46.53 39.25
Support Level $1.57 $4.36
Resistance Level $1.94 $8.29
Average True Range (ATR) 0.15 0.58
MACD 0.04 -0.21
Stochastic Oscillator 52.00 10.37

Price Performance

Historical Comparison
BLND
VNDA

About BLND Blend Labs Inc.

Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segments are; Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience, and the Title segment enables customers to streamline the title, settlement, and closing process at scale for mortgages, home equity lines of credit, and home equity loans. The majority of the revenue for the company is generated from the Blend Platform segment.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: